+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Neurodiagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 115 Pages
  • August 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 4997473
The Neurodiagnostics Market is expected to register a CAGR of 7.5% during the forecast period (2022 - 2027).

The emergence of the COVID-19 pandemic had its impact on the neurodiagnostic market as all the procedures, including diagnostic and therapeutic around the world were impacted due to the decline in visits to hospitals and diagnostic centers because of lockdown restrictions imposed by various governments globally. Further, many studies reported the negative impact of COVID-19 on patients with neurological disorders, which is also expected to impact the studied market. For instance, according to an article published by the National Center for Biotechnology Information, in July 2021, titled "Alzheimer’s and Parkinson’s diseases predict different COVID-19 outcomes: A UK Biobank study", it was observed that the patients with dementia have the highest mortality risk from COVID-19. Thus, the delay in the diagnosis of such diseases during the COVID-19 pandemic has further increased the risk for the patients and negatively impacted the market growth. However, with the resumed services and procedures, and the opening of the diagnostic centers, the neurodiagnostic market is expected to regain its full potential over the forecast period.

The increasing prevalence of neurological disorders, rise in the geriatric population, technological advancements in neurodiagnostic, and growing awareness regarding early diagnosis of diseases are the key driving factors in the neurodiagnostic market.

The rising prevalence of neurological disorders such as Alzheimer's disease, Amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, and spinal muscular atrophy is the key factor driving the demand for the neurodiagnostic market over the forecast period. For instance, For according to the September 2021 report of the World Health Organization, about 55 million people around the world are living with dementia, and nearly 10 million cases are reported every year. Similarly, as reported in National Center for Biotechnology Information, in November 2021, titled "Prevalence of Huntington's Disease", it has been observed that the prevalence of Huntington's disease is around 10 cases per 100,000 people, with a higher prevalence in North America, North-western Europe, the Middle East, and Australia. In these regions, the estimates range from 5.96 to 13.70 cases per 100,000 people. Whereas in Asia, the prevalence is estimated to be 0.41-0.70 cases per 100,000 people.

With the growing prevalence of neurological diseases around the world, government and non-government entities are investing heavily in the development of diagnostics and therapeutics for the treatment, as well as increasing funding and awareness programs for various neurological disorders, which may augment the growth of the market. For instance, in January 2021, Life Sciences Partners (LSP) launched the EUR 150 million LSP Dementia Fund, which is dedicated to combating neurodegenerative diseases. This fund will focus on all stages of dementia drugs and Medtech development to treat neurological diseases in patients.

However, the high cost of diagnostic and imaging systems is likely to hinder the growth of the market.

Key Market Trends

Diagnostic and Imaging Systems Segment is Expected to Hold a Major Market Share

The major factors propelling the growth of the diagnostic and imaging segment include the rising prevalence of neurological disorders, increasing adoption of advanced technologies in medical imaging, and the rising geriatric population.

The increasing burden of neurological disorders among people is increasing the demand for neurodiagnostic devices, which further increases the market growth over the forecast period. For instance, according to a paper published by the Public Health Foundation of India in July 2021, titled " Burden of Neurological disorders in India", the prevalence of non-communicable neurological illnesses is rising in India, owing to the country's aging population. In addition, in India, stroke, headache problems, and epilepsy are the primary causes of neurological illnesses. As per the same source, stroke resulted in the deaths of 699,000 people in 2019, accounting for 7.4% of all deaths in India.

New therapeutic and diagnostic models are being developed that deliver precise results, aid in early disease detection, and reduce the cost of treating various diseases. With the increasing disposable income, people are becoming capable enough to have access to imaging procedures for the early detection of diseases.

Moreover, the increasing company focus on developing innovative imaging and diagnostic products for better and early detection are also contributing to the growth of the market. For instance, in November 2021, Philips launched a new Artificial intelligence-enabled Magnetic Resonance portfolio at the Radiological Society of North America (RSNA) annual meeting in Chicago. Similarly, in March 2021, Hitachi Medical Systems launched two new permanent open MRI systems that are equipped with the SynergyDrive workflow solution at the start of the 2021 European Congress of Radiology. In August 2020, GE Healthcare showcased its three new technologies, SIGNA 7.0T, SIGNA UHP 3.0T, and MAGNUS, to enable neuro research to better understand Alzheimer’s disease and traumatic brain injury as well as accelerate clinical translation.

Thus, the increasing prevalence of neurological diseases and the company's focus on developing well-advanced diagnostic and imaging systems are likely to increase the market growth.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global neurodiagnostic market due to the increasing prevalence of neurological disorders, rising geriatric population, presence of robust healthcare infrastructure, high healthcare spending, and presence of major market players continuously evolving and launching advanced diagnostics devices in the region.

The rising prevalence of neurological diseases is the key factor driving the growth of the market in the region. For instance, in June 2021, in an interview, the Chief Science Officer of the Alzheimer Society of Canada stated that “Over the next 10 years, it was anticipated that more than one million people in Canada will be living with dementia.” This indicates that the increasing prevalence of Alzheimer’s in the North American region is expected to increase the demand for diagnostic and imaging systems, which may further drive the market growth over the forecast period. Similarly, according to the data published by the Parkinson's Foundation, in 2021, an estimated 9,30,000 people were living with Parkinson's disease in the United States 2020, and this number is predicted to increase to 1,2 million by 2030.

Also, the growing geriatric population in the region is expected to increase the burden of neurological disorders, as the geriatric population is more prone to neurodegenerative diseases like Alzheimer’s and Parkinson's, age-associated diseases. For instance, according to the March 2021 report of the Alzheimer’s Association, approximately 6.2 million people of age 65 years and more are living with Alzheimer’s-related dementia in the United States, and it is projected that this number will increase to 13.8 people by 2060.

Moreover, the increasing diagnostic product launches in the region are also contributing to the growth of the market over the forecast period. For instance, In December 2021, Fujifilm Healthcare Americas Corporation presented an advanced high-field open MRI system, Velocity MRI System, at the Radiological Society of North America (RSNA) conference in Chicago.

Hence, the increasing geriatric population, rising burden of neurological disease, and increased product launches are likely to increase the market expansion over the forecast period.

Competitive Landscape

The Neurodiagnostics Market is consolidated and consists of several major players operating in specific segments such as imaging and clinical diagnostics etc. In terms of market revenue, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are GE Healthcare, Siemens Healthineers, Philips Healthcare, Thermo Fisher Scientific, Inc, Hitachi, Ltd, Natus Medical Incorporated, Lifelines Neuro Company, Advanced Brain Monitoring, Inc, and Nihon Kohden Corporation.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Neurological Diseases
4.2.2 Growing Adoption of Novel Diagnostic Technologies
4.3 Market Restraints
4.3.1 High Cost of Diagnosis
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Product Type
5.1.1 Clinical Testing Instruments
5.1.2 Diagnostic and Imaging Systems
5.1.3 Reagents and Consumables
5.2 By End-User
5.2.1 Hospitals and Clinics
5.2.2 Diagnostic Laboratories and Imaging Centers
5.2.3 Other End-Users
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Canon Medical Systems Corporation
6.1.2 Siemens Healthineers
6.1.3 Koninklijke Philips N.V.
6.1.4 Thermo Fisher Scientific, Inc
6.1.5 Fujifilm Corporation
6.1.6 Natus Medical Incorporated
6.1.7 Lifelines Neuro Company
6.1.8 Advanced Brain Monitoring, Inc
6.1.9 Nihon Kohden Corporation
6.1.10 Hoffmann-La Roche Ltd
6.1.11 GE Healthcare
6.1.12 Mitsar Co. LTD

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Canon Medical Systems Corporation
  • Siemens Healthineers
  • Koninklijke Philips N.V.
  • Thermo Fisher Scientific, Inc
  • Fujifilm Corporation
  • Natus Medical Incorporated
  • Lifelines Neuro Company
  • Advanced Brain Monitoring, Inc
  • Nihon Kohden Corporation
  • Hoffmann-La Roche Ltd
  • GE Healthcare
  • Mitsar Co. LTD